Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatWoundAlbino (specific strain not stated)Both sexesn = n=25 adult rats for the wound healing study (five groups of…Topical to the wound; oral for the acute toxicity (LD50) studyTopical extract at 5, 20 and 50 mg/mL w/v; acute toxicity (…After wound creation; exact interval not stated
Model: Incision skin wound (1.5 cm) created with a surgical blade under anaesthesia
Extract concentrations of 5, 20 and 50 mg/mL w/v produced significant (ANOVA, P<0.05) healing of the incision wounds, giving 125% to 140% healing versus control (100%), while Neobacin gave 150% healing at the third treatment regimen. Extract yield was 49.80% w/w dry matter and the LD50 was beyond t…
Extraction: extract · Supplied extraction confidence: 0.72. Machine-extracted fields require source verification.